President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
Clinical Research50-Year Medalist Study
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

News Release

Joslin Diabetes Center Presenting More Than 40 Presentations at the 73rd American Diabetes Association Scientific Sessions

Research Validates 115 Year Old Institution’s Commitment to Advancing Research and Discovery into Diabetes Treatments

Boston, Mass - June 20, 2013 – Joslin Diabetes Center, the world's largest diabetes research and clinical care organization committed to the improvement of diabetes treatment and the pursuit of a cure, today announced it will present more than 40 oral and poster presentations at the 73rd American Diabetes Association Scientific Session in Chicago June 21-25.

Joslin researchers will present research involving but not limited to vascular cell biology, clinical and behavioral and integrated physiology and metabolism research. In addition, Joslin CEO John L. Brooks will be sharing Joslin’s perspective on new, innovative approaches in diabetes care on June 22. 

“Diabetes is growing at an alarming rate. It strikes nearly 26 million Americans – one quarter of them do not even know they have it. Recent estimates project that as many as 1 in 3 American adults will have diabetes by 2050,” said president and CEO John Brooks. “For 115 years, Joslin Diabetes Center has remained committed to leading diabetes research in the pursuit of finding new treatments and improving patient care. Our researchers are thrilled to have an opportunity to present our findings and demonstrate our significant progress.”

“Because of Joslin’s singular focus on diabetes, this annual meeting is a critical time for us to assess our research and determine how far we’ve collectively moved the needle toward our goal of improving diabetes prevention and treatment,” said Dr. George King, Chief Scientific Officer of The Joslin Diabetes Center.  “With more than 40 presentations and three of those selected as a presidential oral session, I am very excited that the efforts of all our Joslin researchers are helping to understand significantly the causes of diabetes and its complications.”

Specific studies to be presented include:
June 21, 4:15-6.15 p.m.

• Overexpression of IRS1 and Enhanced Insulin Actions  (Lead author: Kyoungmin Park)
• Intestinal Epithelial Insulin Signaling Plays an Important Role in the Regulation of Whole Body Glucose and Lipid Homeostasis (Lead author: Siegfried Ussar)
• Exercise Training Alters Subcutaneous White Adipose Tissue (SCWAT) in Mice and Humans (Lead author: Kristin Stanford)
• Controlled Behavioral Interventions: Impact of Weight Loss on Type 2 Diabetes Patients (Lead author: Allison Goldfine)

June 22, 8:00 – 10:00
• Intestinal Epithelial Insulin Signaling Plays an Important Role in the Regulation of Whole Body Glucose and Lipid Homeostasis (Lead author: Siegfried Ussar)

June 22, 11:30 a.m.
• Long-Term Weight Management  (Lead author: Osama Hamdy)

June 23, noon:
• Comparative Effectiveness of Roux-en-Y Gastric Bypass Versus Intensive Diabetes and Weight Management in Obese T2D (Lead author: Allison Goldfine)